Compare Ginkgo Bioworks Holdings Inc (DNA) vs Lithium Americas Corp (LAC) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

Lithium Americas (LAC) trades at $2.34, down 2.9% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company shows negative profitability metrics with ROE at -9.56% and ROA at -3.99%, though it has beaten earnings expectations in recent quarters. Cash flow remains supported by financing activities as the company invests heavily in Thacker Pass development. Analyst consensus is mixed with 7 buy ratings and 8 hold ratings, with a $4.00 price target representing 71% upside potential.

LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The primary catalyst is successful construction and operation of Thacker Pass, but investors face significant execution risk, negative cash flow from operations, and lithium price volatility. The stock trades at a discount to book value (P/B 0.6), offering potential upside if operational milestones are met.